Sandra Van Schaeybroeck

Dr

  • Room 03.010 - CCRCB

    United Kingdom

Accepting PhD Students

PhD projects

Dr. Van Schaeybroeck is interested in PhD applications from candidates with a basic science or clinical background in the fields of; - Laboratory based investigations into molecular mechanisms including altered pro-survival signaling pathways in RASMT and BRAFMT CRC - Discovery of novel resistance mechanisms to therapy mechanisms in RASMT and BRAFMT CRC - Innovative biomarker development using samples from RASMT and BRAFMT CRC patients

20022019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Sandra Van Schaeybroeck is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 37 Similar Profiles
Colorectal Neoplasms Medicine & Life Sciences
Mitogen-Activated Protein Kinase Kinases Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Drug Resistance Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Apoptosis Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Caspase 8 Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2012 2018

Research Output 2002 2019

23 Downloads (Pure)

A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic

Salvucci, M., Rahman, A., Resler, A. J., Udupi, G. M., McNamara, D. A., Kay, E. W., Laurent-Puig, P., Longley, D. B., Johnston, P. G., Lawler, M., Wilson, R., Salto-Tellez, M., Van Schaeybroeck, S., Rafferty, M., Gallagher, W. M., Rehm, M. & Prehn, J. H. M., 17 Apr 2019, In : JCO Clinical Cancer Informatics. 17 p.

Research output: Contribution to journalArticle

Open Access
File
Protein Array Analysis
Colorectal Neoplasms
Proteins
Immunohistochemistry
Workflow

Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours

McDaid, W. J., Greene, M. K., Johnston, M. C., Pollheimer, E., Smyth, P., McLaughlin, K., Van Schaeybroeck, S., Straubinger, R. M., Longley, D. B. & Scott, C. J., 18 Oct 2019, In : Nanoscale. 13 p.

Research output: Contribution to journalArticle

Chemotherapy
Epidermal Growth Factor Receptor
Antibodies
Tumors
Nanoparticles

A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours

Wilson, R., Dass, P. H., Van Schaeybroeck, S., Elez, E., Quinton, A., Jones, R., Houlden, J., Collins, L., Roberts, C., Love, S., Lawler, M., Di Nicolantonio, F., Grayson, M., Bardelli, A., Laurent=puig, P., Maughan, T., Tabernero, J., Peeters, M., Middleton, M. & Rolfo, C., Nov 2018, In : European Journal of Cancer. 103, Suppl 1, p. e140-e141

Research output: Contribution to journalMeeting abstract

Mitogen-Activated Protein Kinase Kinases
Neoplasms
Creatinine
Phosphotransferases
Fatigue

Corrigendum: Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges

Bradley, C. A., Salto-Tellez, M., Laurent-Puig, P., Bardelli, A., Rolfo, C., Tabernero, J., Khawaja, H. A., Lawler, M., Johnston, P. G., Van Schaeybroeck, S. & MErCuRIC consortium, 23 Jan 2018, In : Nature reviews. Clinical oncology. 15, 3, p. 150 1 p.

Research output: Contribution to journalArticle

Neoplasms
corrigendum

Targeting the dopamine receptor 2 in BRAF mutant colorectal cancer

Javadi, A., Forsythe, N., Refaat, A., Weir, J-A., Khawaja, H., Waugh, D., Tarapore, R., Allen, J. E., Johnston, P. & Van Schaeybroeck, S., Jul 2018, In : Cancer Research. 78, Issue 13 Supplement, 1 p., Abstract 3448.

Research output: Contribution to journalMeeting abstract

Activities 2008 2019

Internal examiner

Sandra Van Schaeybroeck (Examiner)
2019

Activity: Examination typesOther examination

COLOSSUS CRC PPI event at RCSI

Sandra Van Schaeybroeck (Keynote speaker)
30 Apr 2019

Activity: Talk or presentation typesInvited talk

Daniel Hochhauser

Sandra Van Schaeybroeck (Host)
09 May 2019

Activity: Hosting a visitor typesHosting an academic visitor

Targeting poor prognostic molecular subtypes in colorectal cancer

Sandra Van Schaeybroeck (Keynote speaker)
17 May 2019

Activity: Talk or presentation typesInvited talk

Molecular Cancer Therapeutics (Journal)

Sandra Van Schaeybroeck (Peer reviewer)
25 Sep 2018

Activity: Publication peer-review and editorial work typesPublication peer-review

Press / Media

Queen’s researchers discover ground-breaking process which destroys bowel cancer cells

Sandra Van Schaeybroeck, P.G. Johnston, P.G. Johnston & P.G. Johnston

06/09/2018

8 items of Media coverage

Press/Media: Research